Managing Director & Senior Partner
Michael Choy joined Boston Consulting Group in 2005 and has worked in the New Jersey, San Francisco, and Shanghai offices. He is a leader in BCG's work in the US on COVID-19 crisis response and vaccine development and deployment; and is also one of the firm’s experts in cell and gene therapy, defining strategies and operations for new therapeutic modalities.
Michael has extensive experience serving industry-leading clients in the US, Europe, and Asia on high-impact programs, developing strategies, delivering innovative solutions, leading large teams, guiding executive decision-making, and driving client relationships. He has worked with clients on R&D, manufacturing, and commercialization of new medicines; large-scale change and PMI; R&D governance, organization, and operations; population health and disease surveillance; market access and commercialization; and global health.
Michael is an infectious disease epidemiologist by training, and has held research positions at Stanford and the University of California, San Francisco.
Lessons learned during COVID-19 present an opportunity to improve the US public health system. Expanding practitioners’ capacities in decision-making, communication, and working with data is a critical step.
LNPs are well-positioned to support the emerging field of genomic medicines, for which safety and efficient in vivo delivery has been a key challenge.
Pharma has invested billions in cell and gene therapies. Gene editing is making a case for more of this funding, but companies need to understand what they’re investing in and why.
US states face the delicate task of scaling back their COVID-19 public-health infrastructure while ensuring that they are better prepared for the next crisis.
The head of the FDA’s Center for Biologics Evaluation and Research discusses key areas of progress in CGT, ways to streamline regulatory review, and more.
A new wave of innovation is coming. Pharma companies need to determine the role they will play in shaping it.
Biopharma companies should approach the coming year with a clear view of shifting expectations and market conditions.
Companies can maximize the value of large-scale mergers by proactively implementing a transparent, disciplined talent-selection process.
Preparing Localities for Action Against Novel Coronavirus (PLAN) is a scenario-planning tool that identifies potential US supply and demand imbalances down to the county level.
These curative treatments are often unique. They face a very different type of marketplace.
These new therapies are poised to revolutionize oncology. It all depends on reaching a larger patient base and simplifying manufacturing and the supply chain.